Ka Lai Yee

Merck & Co., Inc., Rahway, NJ, USA (United States)

MedicineImmunology and MicrobiologyPharmacology, Toxicology and PharmaceuticsNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014”.

Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014

JAIDS Journal of Acquired Immune Deficiency Syndromes(2022)10.1097/qai.0000000000003116

N/A

0DataRank · unranked

3 citations

Ka Lai Yee, Kathryn P. Gray, Mounika Yedla, Hong Wan, Nicole H. Tobin +17 more